Challenges in the management of endometrial cancer and endometrial hyperplasia with atypia in sub-fertile patient: an emerging medical issue-our experience in a tertiary care centre
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20222975Keywords:
Endometrial carcinoma, Endometrial hyperplasia with atypia, Nulliparous, Fertility preservation, Progestins, Original study, Tertiary centreAbstract
Background: The cases of endometrial hyperplasia with atypia/endometrial carcinoma with age below 40 years are rising and many are nulliparous at diagnosis. The purpose of the study was to study the oncological and obstetric outcome among young women with above mentioned endometrial pathology treated with fertility preserving approach.
Methods: The retrospective cohort approach included 17 patients who visited Bhagwan Mahaveer Jain Hospital from January 2016 to January 2022 with a diagnosis of endometrial hyperplasia with atypia/endometrial carcinoma who met national comprehensive cancer network criteria. The records of all the patients included in the study have been reviewed retrospectively.
Results: In our study 13/17 (76.47%) patients showed complete response to hormonal treatment. Conception rates are low (23.07%) even after reversal of the malignancy. Thirteen of 17 patients had associated polycystic ovarian syndrome. Three out of 17 (17.64%) had progressive disease, 5/13 (38.46%) cases had disease recurrence after initial remission out of which 3 had rechallenge with progestins with remission again.
Conclusions: Levonorgestrol intra uterine system along with oral progestins is an effective combination as device might be useful in optimising the dose of oral progestins without the need for further escalation of dosage. Levonorgestrol intra uterine device or low dose oral progestins alone should be continued in responders not opting for conception as maintenance hormonal therapy. Hysterectomy should be advised if hormonal treatment fails, and also after completion of childbearing. Myometrial invasion may not be absolute contraindication for fertility sparing treatment. Molecular profiling of endometrial biopsy might help in better prognostication and treatment strategy.
References
Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol. 2005;193(5):1640-4.
Fujiwara H, Ogawa S, Motoyama M, Takei Y, Machida S, Taneichi A, et al. Frequency and characteristics of endometrial carcinoma and atypical hyperplasia detected on routine infertility investigations in young women: a report of six cases. Hum Reprod. 2009;24(5):1045-50.
Navarria I, Usel M, Rapiti E, Neyroud-Caspar I, Pelte MF, Bouchardy C, Petignat P. Young patients with endometrial cancer: How many could be eligible for fertility-sparing treatment? Gynecol Oncol. 2009;114:448-51.
American Cancer Society. Survival by Stage of Endometrial Cancer. 2018. Available at: https://www.cancer.org/cancer/endometrial-cancer/ detection-diagnosis-staging/survival-rates.html. Accessed on 15 November 2020.
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterineneoplasms, Version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(2):170-99.
Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009;114(1):128-34.
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607-18.
American Cancer Society. Surgery for Endometrial Cancer; American Cancer Society: Atlanta, GA, USA. 2017. Available at: http://www.ecoeco.org/publica/ encyc.htm. Accessed on 5 November 2021.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41.
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, Amant F, et al. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020;63(4):417-31.
Stewart K, Campbell S, Frumovitz M, Ramirez PT, McKenzie LJ. Fertility considerations prior to conservative management of gynecologic cancers. Int J Gynecol Cancer. 2021;31(3):339-344.
Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95(1):133-8.
Ayhan A, Tohma YA, Tunc M. Fertility preservation in early-stage endometrial cancer and endometrial intraepithelial neoplasia: A single-center experience. Taiwan J Obstet Gynecol. 2020;59(3):415-9.
Fang F, Xu H, Wu L, Hu L, Liu Y, Li Y, Zhang C. LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia. Am J Transl Res. 2021;13(5):5412-9.
Grandi G, Farulla A, Sileo FG, Facchinetti F. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19:677-86.
Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207:266.
Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49(4):868-74.
Obermair A, Baxter E, Brennan DJ, McAlpine JN, Muellerer JJ, Amant F, et al. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020;63(4):417-31.
Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019;153(3):487-95.
